May 16 (Reuters) - Immunovaccine Inc IMV.TO
* Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored phase 2 clinical trial in DLBCL in combination with approved anti-PD-1 drug
* Immunovaccine Inc says expects trial to begin enrolling patients following receipt of regulatory clearance from Health Canada Source text for Eikon: ID:nMKW92fcFa Further company coverage: IMV.TO